Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
| ▸ | SELL | P14151 | 1/20 | 0.43 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3805126 | 0.86 | DPP4 (0.47) | DPP4AKR1C2AKR1C1ALDH1A1TSHR | |
| SCHEMBL4143093 | 0.83 | GRM1 (0.51) | DPP4AKR1C2AKR1C1ALDH1A1TSHR | |
| SCHEMBL27544752 | 0.83 | CSNK2A2 (0.49) | ALDH1A1TSHRTP53CASP1SMN1; SMN2 | |
| SCHEMBL4670497 | 0.81 | TSHR (0.52) | AKR1C2AKR1C1ALDH1A1TSHRTP53 | |
| SCHEMBL10533170 | 0.80 | SELL (0.60) | DPP4AKR1C2AKR1C1ALDH1A1TSHR | |
| SCHEMBL27280575 | 0.79 | DPP4 (0.52) | DPP4ALDH1A1TSHRTP53CASP1 | |
| SCHEMBL597387 | 0.79 | ABL1 (0.46) | ALDH1A1TSHRCASP1SMN1; SMN2KDM4E | |
| SCHEMBL30988009 | 0.78 | ALDH1A1 (0.57) | ALDH1A1TSHRKDM4EHSD17B10MEN1 | |
| SCHEMBL30589153 | 0.78 | SELL (0.64) | ALDH1A1TSHRCASP1SMN1; SMN2KDM4E | |
| SCHEMBL2500795 | 0.78 | ALDH1A1 (0.57) | ALDH1A1TSHRKDM4EHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137158-A1 | DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| WO-2022116998-A1 | FUSED HETEROCYCLIC DERIVATIVES AS HBV INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022116998-A1 | FUSED HETEROCYCLIC DERIVATIVES AS HBV INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |
| US-20200270240-A1 | BENZOTHIAZOLE AND PYRIDOTHIAZOLE COMPOUNDS AS SUMO ACTIVATORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200270240-A1 | BENZOTHIAZOLE AND PYRIDOTHIAZOLE COMPOUNDS AS SUMO ACTIVATORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2020-07-23 | — | — | US | disclosed |
| EP-2536706-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2012-12-26 | — | — | EP | disclosed |
| CN-102822165-A | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORP | 2012-12-12 | — | — | CN | disclosed |
| WO-2011100380-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CELGENE CORPORATION | 2011-08-11 | — | — | US | disclosed |
| EP-0535192-B1 | NOVEL DNA GYRASE INHIBITORS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | HOFFMANN LA ROCHE (CH) | 1996-06-19 | — | — | EP | disclosed |
| US-5486466-A | ENZYME INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1996-01-23 | — | — | US | disclosed |
| US-5399741-A | DNA gyrase inhibitors, process for their manufacture and pharmaceutical preparations containing same | HOFFMANN-LA ROCHE INC. (US) | 1995-03-21 | — | — | US | disclosed |
| US-5294609-A | Microbiocides | HOFFMANN-LAROCHE INC. (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0535192-A1 | NOVEL DNA GYRASE INHIBITORS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME. | HOFFMANN LA ROCHE (CH) | 1993-04-07 | — | — | EP | disclosed |
| WO-1992018490-A1 | NOVEL DNA GYRASE INHIBITORS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | F. HOFFMANN-LA ROCHE AG (CH) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196150-A1 | Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same | CYP3A7, CYP3A4, CYP3A43 | DPP4 145/4885AKR1C2 1221/4885AKR1C1 1719/4885 |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | DPP4 145/4885AKR1C2 1221/4885AKR1C1 1719/4885 |
| US-20200270240-A1 | BENZOTHIAZOLE AND PYRIDOTHIAZOLE COMPOUNDS AS SUMO ACTIVATORS | SUMO2, ATP2A2, ATP2A1 | DPP4 1618/4885AKR1C2 3648/4885AKR1C1 3864/4885 |
| US-20200231567-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | DPP4 145/4885AKR1C2 1221/4885AKR1C1 1719/4885 |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | DPP4 145/4885AKR1C2 1221/4885AKR1C1 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.